GLP-1 receptor agonists

Cardiovascular outcomes, non-diabetic indications, safety signals.

Semaglutide, tirzepatide, and next-gen GLP-1/GIP agonists are reshaping obesity, CV risk, NAFLD, and even neuropsychiatric research. Relaylit keeps clinicians current on new trials, off-target effects, and emerging indications.

Example brief

"GLP-1 receptor agonists beyond diabetes: obesity, heart failure, NAFLD. RCTs and meta-analyses only."

Paste this into your Relaylit profile and tweak. First digest arrives within hours.

Where Relaylit searches for this topic

PubMed

35M+ biomedical citations from MEDLINE, life-science journals, and online books.

About PubMed →

Europe PMC

42M+ life science citations, including preprints and full-text open-access papers.

About Europe PMC →

Crossref

155M+ records covering journals, conference proceedings, books, and preprints with DOIs.

About Crossref →

How Relaylit tracks glp-1 receptor agonists

1. Describe it once

Paste a plain-language brief for glp-1 receptor agonists. No boolean operators, no saved-search syntax.

2. We search 3 databases

Relaylit queries PubMed, Europe PMC and Crossref on the live APIs, deduplicates the results, and ranks each paper against your brief.

3. Read the digest

A focused, ranked email lands weekly, biweekly, or monthly — the strongest glp-1 receptor agonists work, not a raw feed.

Frequently asked questions

Which research databases does Relaylit search for glp-1 receptor agonists?

Relaylit searches PubMed, Europe PMC and Crossref for glp-1 receptor agonists. Every result is pulled from the live APIs each time your digest is generated, so new work reaches you within hours of being indexed.

How often will I get glp-1 receptor agonists updates?

You choose the cadence — weekly, biweekly, or monthly. Each digest ranks every new match against your brief and emails you a focused, ranked selection instead of a raw feed.

Can I customise what counts as relevant?

Yes. You write a plain-language brief — for example: "GLP-1 receptor agonists beyond diabetes: obesity, heart failure, NAFLD. RCTs and meta-analyses only." — and Relaylit ranks every result against it. Tighten or broaden the brief any time.

Is tracking glp-1 receptor agonists free?

Relaylit is free for up to two topics, so you can track glp-1 receptor agonists at no cost. Paid plans add more topics and higher frequency.

Ready to track this?

Your first glp-1 receptor agonists digest lands this week.

Start free